Alto Neuroscience officer proposes $2.22M share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Alto Neuroscience, Inc. (ANRO) officer Michael Hanley filed a notice for the proposed sale of 75,000 common shares, with an aggregate market value of $2,215,500 and an approximate sale date of November 16, 2026. The notice says the shares were and will be received through stock-option exercises over the next three months, with acquisition and payment dates tied to the exercise and sale dates. It lists August 14, 2026 as the plan adoption or instruction date for Rule 10b5-1 reliance.
Key Figures
Key Terms
Rule 10b5-1 regulatory
stock options financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.